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Abstract Niemann–Pick disease type C (NP-C) is a fatal
progressive neurolipidosis involving neuronal storage of
cholesterol and gangliosides. Miglustat, an inhibitor of
glycosphingolipid synthesis, has been approved to treat
neurological manifestations in adults and children with NP-
C. This open-label observational study in adults with
confirmed NP-C evaluated the efficacy of miglustat
(200 mg t.i.d.) based on composite functional disability
(CFD) scores and brain proton magnetic resonance spec-
troscopy (H-MRS) measurement of choline (Cho)/N-acetyl
aspartate (NAA) ratio in the centrum ovale. Overall, 16
patients were included and received miglustat for a mean
period of 30.6 months: 12 continued on miglustat
throughout follow up, and 4 discontinued miglustat
because of adverse effects (n = 2) or perceived lack of
efficacy (n = 2). In the ‘continued’ subgroup, the mean
(SD) annual progression of CFD scores decreased from
0.75 (0.94) before treatment to 0.29 (1.29) during the
period between miglustat initiation and last follow-up. In
the discontinued subgroup, CFD progression increased
from 0.48 (0.44) pre-treatment to 1.49 (1.31) at last follow
up (off treatment). Mean (SD) Cho/NAA ratio [normal
level 0.48 (0.076)] decreased during miglustat treatment in
the continued subgroup: 0.64 (0.12) at baseline (miglustat
initiation), 0.59 (0.17) at 12-month follow up, and 0.48
(0.09) at 24-month follow up. Cho/NAA ratio remained
relatively stable in the discontinued subgroup: 0.57 (0.15),
0.53 (0.04) and 0.55 (0.09), respectively. In conclusion,
H-MRS Cho/NAA ratio might serve as an objective,
quantitative neurological marker of brain dysfunction in
NP-C, allowing longitudinal analysis of the therapeutic
effect of miglustat.
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Introduction
Niemann–Pick disease type C (NP-C) is a rare lysosomal
storage disorder of autosomal recessive inheritance that is
characterised by progressive neurological deterioration and
premature death. The incidence of NP-C has been esti-
mated at between 1:89,000 and 1:120,000 live births [18,
33]. NP-C arises from mutations in either of two genes,
NPC1 (in 95 % of patients) and NPC2, which code for
proteins that play roles in intracellular cholesterol and
glycolipid trafficking [29]. Deficiencies in NPC1 or NPC2
protein products leads to the accumulation of large
amounts of free cholesterol and sphingomyelin in various
peripheral organs and glycosphingolipids (primarily GM2
and GM3 gangliosides) in the brain. The mechanisms
through which brain gangliosides accumulate are probably
multiple, and the relationship between glycolipid storage
and abnormalities in cholesterol transport are still contro-
versial [29].
While the majority of cases of NP-C reported to date
relate to disease onset during infancy or childhood,
increased numbers of patients with the adolescent/adult-
onset form have been detected over the last decade [9, 12,
26, 30, 32]. Adult-onset NP-C is usually associated with
psychiatric disorders, cognitive decline, vertical supranu-
clear ophthalmoplegia (VSO), cerebellar ataxia, movement
disorders, gelastic cataplexy and hepatosplenomegaly [18,
31]. On average, death occurs approximately 12 years after
the onset of psychiatric or neurological signs [26].
N-Butyl-deoxynojirimycin (miglustat) is an inhibitor of
glucosylceramide synthetase that was initially approved for
the treatment of Gaucher disease type I. As miglustat also
inhibits the biosynthesis of all glycolipids derived from
glucosylceramide, including most gangliosides, it was
tested in animal models of NP-C and other neurolipidoses,
and was observed to delay onset of neurological symptoms,
increase survival and improve brain neuropathology [14,
27, 36]. A randomised controlled clinical trial reported
stabilisation or improvement of horizontal saccade veloc-
ity, swallowing and ambulation in patients with NP-C [21].
These initial results have since been supported in numerous
observational prospective or retrospective studies, small
case series, and some case reports among patients with the
juvenile and adult forms of the disease [4–6, 11, 15, 17, 19,
20, 22, 23, 25, 34, 35]. Clinical benefits appear less pro-
nounced in infantile NP-C, although a degree of delay in
disease progression has been reported [11, 15, 22, 23].
There is additional evidence that miglustat could stabilise
or even improve some brain imaging parameters measured
with positron emission tomography or diffusion tensor
imaging [22, 25], as well as cerebrospinal fluid biomarkers
such as b-amyloid and T-Tau [16].
Proton magnetic resonance spectroscopy (MRS) is an
objective, quantitative method for measuring brain function
in situ [10]. It is non-invasive and is performed routinely in
most academic hospitals. The MRS choline (Cho) peak
increases in several pathological circumstances associated
with membrane instability including glial proliferation,
myelin breakdown and abnormal lipid storage. Neurolipi-
doses usually cause increased choline levels in brain white
matter [8, 10, 28]. In contrast, the MRS NAA (N-acety-
laspartate) peak reflects neuronal viability, with a decrease
in NAA considered as a hallmark of neuronal or axonal
injury [24]. The Cho/NAA ratio integrates both choline-
and NAA-related changes. Although it is not a specific
parameter, it is a quantitative measure and might be useful
for monitoring treatment effects in brain neurolipidoses.
In a previous publication we reported that treatment with
miglustat could enable attainment of a normal Cho peak
based on a follow-up study of three patients with NP-C
treated for 24 months [8]. Here we investigate this finding
further in a multicentre observational study in 16 adult NP-
C patients treated with miglustat.
Methods
Patients and study design
Between March 2006 and July 2012, 16 adult patients with
confirmed NP-C (based on positive filipin staining and
identification of two NP-C gene mutations) were included
in an observational study at three French centers: Pitie´-
Salpeˆtrie`re Hospital, Paris; Centre Hospitalo-Universitaire
de Strasbourg; and La Timone Hospital, Marseille. Patients
were included regardless of disease severity, neurological
form (based on age at neurological onset), and treatment
status.
Patients were evaluated every 6–12 months in line with
current recommendations for the clinical management of
NP-C [18]. The observation period varied from patient to
patient based on the interval between the onset of neuro-
logical symptoms and last follow up. Miglustat initiation
was taken as baseline for outcome assessments, with any
assessments conducted before miglustat initiation assigned
‘pre-treatment’ and those conducted after miglustat initia-
tion assigned as ‘post-baseline’. Miglustat was adminis-
tered as per manufacturer’s instructions [1]. In all patients,
treatment was commenced after the first appearance of
neurological manifestations.
The study was coordinated by the French Committee for
Evaluation of Treatments for Niemann–Pick diseases
(CETNP), and was performed in accordance with relevant
institutional ethical review board criteria as well as ethical
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standards specified in the 1964 Declaration of Helsinki and
its later amendments. All patients provided written
informed consent for all study procedures and data
reporting.
Functional disability assessments
At each clinical evaluation, patient functional disability
was assessed using a disease-specific disability scale for
NP-C that assessed four key neurological domains:
ambulation, manipulation, language and swallowing [13].
A composite functional disability (CFD) score was calcu-
lated for each patient as the sum of all four individual
disability domains, where scores ranged from 4 (best) to 18
(worst), as described previously [13]. For patients who
commenced miglustat after onset of neurological mani-
festations, disability scores were calculated retrospectively
between neurological onset (pre-treatment) and miglustat
initiation (baseline), and prospectively throughout miglus-
tat therapy up to last follow up (the post-baseline period).
For patients who commenced miglustat at neurological
onset, all disability score assessments were prospective up
to last follow up.
MRS assessments
Brain MRS was also performed at each clinic visit at Sal-
peˆtrie`re Hospital, Paris, France, using a 3T MR unit (Gen-
eral Electric, WI, USA) with a single-voxel acquisition
using the PRESS sequence at long echo time
(TR = 1500 ms; TE = 135 ms) in the white matter of the
centrum ovale. The volume of interest was similarly located
in all acquisitions and measured 40 9 16 9 20 mm (x, y,
z axes). Spectra with a poor peak resolution were excluded
from analyses. Resonances of Cho at 3.26 ppm, creatine
(Cr) at 3.3 ppm, and NAA at 2.02 ppm were automatically
quantified by the software provided by the manufacturer
(Probe Q, General Electric Medical Systems, WI, USA).
The Cho/NAA ratio was then calculated.
Statistical analyses
Individual annual rates of progression in functional dis-
ability were calculated for each patient based on all
available CFD score data obtained during pre-treatment
and post-baseline observation using linear regression
analysis (see supplement 1, model 1) [7]. Values were
calculated for two patient subgroups: (1) patients who
remained on treatment up to last follow up visit (‘continued
treatment’ subgroup), and (2) patients who discontinued
treatment before the last follow up visit (‘discontinued
treatment’ subgroup). Pre-treatment and post-baseline
annual CFD progression rates were calculated using a
linear mixed effects model that included separate terms for
patient subgroups and study period (‘pre-treatment’ vs
‘post-baseline’; see supplement 1, model 2). Annual rates
of progression of Cho/NAA ratio were calculated similarly
for individual patients for the ‘post-baseline’ period (see
supplement 1, model 3).
Similar linear regression analyses were applied to assess
any correlation between the post-treatment initiation
annual CFD progression rate and the post-treatment initi-
ation Cho/NAA progression rate. Raw data for MRS Cho/
NAA values were calculated based on approximate time
points: the actual time of measurement was within
2 months of stated time points.
All statistical tests were performed using the two-sided
significance level of a = 0.05. All statistical analyses were
conducted using SAS v. 9.3.
Results
Patients and treatment
Individual patient data on clinical, biological and genetic
characteristics are summarised in Table 1, and descriptive
statistics for the overall cohort and continued and discon-
tinued patient subgroups are provided in Table 2. Patients
1, 3–6, 9, 10 and 12–16 were followed up in the Pitie´-
Salpeˆtrie`re Hospital (Paris, France), patients 2, 7, 8 and 11
were followed up in La Timone Hospital (Marseille,
France), and patient 14 was followed up in the Hautepierre
Hospital, Strasbourg, France.
There were nine males and seven females, overall. The
median (range) age at neurological symptom onset in the
whole cohort was 16.5 (9–32) years, and the median
(range) age at treatment start was 23.0 (14–41) years. Both
median age at neurological onset and median age at
treatment start tended to be higher in patients who dis-
continued miglustat during the observation period, than in
those who continued on miglustat.
In the whole study cohort, patients were treated with
miglustat for a mean (SD) of 30.6 (27.3) months; median
(range) 19.5 (6–96) months. Miglustat was well tolerated in
the 12 patients in whom therapy was continued throughout
follow up (the ‘continued’ subgroup). Patients 13–14, 15
and 16 discontinued miglustat therapy before the last fol-
low-up visit. These patients (the ‘discontinued’ subgroup)
spent a mean (SD) period of 16.6 (14.6) months off treat-
ment between miglustat initiation and last follow up.
Treatment was stopped after 14 months in patients 13 and
15 due to continuous symptom progression and severe
dementia. Patient 14 stopped treatment after 6 months due
to lack of motivation following weight loss and tremor.
Patient 16 stopped treatment after 1 month because of
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severe depression and attempted suicide. He then re-started
treatment when his depressive thoughts resolved, but a later
recurrence of severe depression and autoagressive beha-
viour led to definitive treatment discontinuation after an
overall period of 5 months on miglustat.
Functional disability
The mean (SD; range) total period for CFD assessments
(i.e., the sum of pre-miglustat initiation retrospective
assessments and assessments conducted during follow-up
after miglustat initiation) was 8.7 (7.8, 1–25) years. The
mean (SD; range) observation periods between miglustat
initiation and last follow up in the continued subgroup
(n = 12) and the discontinued subgroup (n = 4) were 7.3
(7.2, 1–25) years and 13.4 (9.3, 3–22) years, respectively
(Table 2).
The mean (SD) overall CFD score at treatment initiation
in the whole patient cohort was 8.53 (1.81). Figure 1 shows
individual and average predicted CFD scores over the
entire observation period. In the continued subgroup, mean
(SD) CFD scores among 12 patients with available data
were 8.42 (1.68) at treatment initiation and 8.67 (1.42) at
last follow up, compared with 7.75 (3.30) and 10.75 (4.50)
among patients with available data in the discontinued
subgroup.
The mean (SD) pre-treatment annual rate of progression
of CFD scores in the continued subgroup was 0.75 (0.94)
based on patients with both pre- and post miglustat initia-
tion data (n = 10), which decreased to 0.29 (1.29) among
12 evaluable patients during the post-baseline period. Mean
(SD) annual pre-treatment and post-initiation progression
rates among the four evaluable patients in the discontinued
subgroup were 0.48 (0.44) and 1.49 (1.31), respectively.
From the linear mixed modelling analysis, the calculated
mean (95 % CI) difference in pre-treatment and post-
baseline annual CFD progression rates in the continued
subgroup was -0.35 (-0.52, -0.18)—a statistically sig-
nificant reduction (p\ 0.001). Further, the post-baseline
progression rate in this subgroup [0.087 (-0.05, 0.22)] was
not statistically significantly different from zero
(p = 0.193). In the discontinued subgroup, the mean (95 %
CI) pre-treatment versus post-baseline difference in annual
progression rate [0.82 (0.52, 1.13)] was also statistically
significant (p\ 0.001), indicating an increase in the pro-
gression rate. In this subgroup the mean post-baseline
progression rate was statistically significantly different
compared to zero [1.11 (0.84, 1.38); p\ 0.001].
Change in Cho/NAA ratio over time
All patients in the cohort had at least one brain white
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periods were 2.3 (1.7, 0.5–5.4) years in the overall patient
cohort (n = 14 evaluable patients), 2.6 (1.9, 0.5–5.4) years
in the continued subgroup (n = 11 evaluable patients), and
1.4 (0.1, 1.4–1.5) years in the discontinued subgroup
(n = 3 evaluable patients).
Absolute Cho/NAA ratio values tended to decrease over
time during miglustat treatment in the overall patient cohort
(Table 3). The mean (SD) Cho/NAA ratio at miglustat ini-
tiation was 0.63 (0.12), which decreased to 0.56 (0.09) by 18
(±2) months in the ‘post-baseline’ period. Respective mean
(SD) baseline (miglustat initiation) and 18-month values
were 0.64 (0.12), and 0.54 (0.07) in the continued subgroup,
and 0.57 (0.15) and 0.60 (0.13) in the discontinued sub-
group. These data can be considered against mean (SD)
normal Cho/NAA ratio values [0.48 (0.076)] from a previ-
ous study involving 12 healthy adults (Personal Communi-
cation, D Galanaud, 2014). During further long-term follow-
up in the continued patient subgroup, albeit based on rela-
tively limited observation numbers, Cho/NAA ratio values
were maintained at approximately the same level up to last
follow up [mean (SD) 0.43 (0.07) at month 50 ± 2 months;
n = 3]. One patient from the discontinued subgroup (patient
13) had Cho/NAA ratio values of 0.61 and 0.65 at months 36
and 50, respectively.
Based on linear mixed modelling analysis (Fig. 2), the
mean (95 % CI) annual progression rate of Cho/NAA
ratios decreased among patients with available data
(n = 11) in the continued subgroup by -0.032 (-0.036,
-0.027) and increased among three evaluable patients in
the discontinued subgroup by 0.015 (–0.005, 0.026).
Relationship between CFD score and Cho/NAA
ratio progression rates
The relationship between CFD and Cho/NAA ratio pro-
gression rates was evaluated based on findings from linear
mixed regression modelling, with 95 % prediction and
confidence intervals (Fig. 3). This analysis showed a high
degree of correlation between annual rates of progression
for CFD score and annual rates of progression of Cho/NAA
ratios, with a correlation coefficient of 0.88 (p\ 0.001).




subgroup (N = 12)
Discontinued treatment
subgroup (N = 4)
Age at neurological onset (years)
Mean (SD) 18.3 (6.9) 16.8 (6.0) 22.8 (8.6)
Median (range) 16.5 (9–32) 15.5 (9–32) 22.5 (14–32)
Age at treatment start (years)
Mean (SD) 25.7 (8.5) 23.2 (8.1) 33.3 (4.3)
Median (range) 23.0 (14–41) 22.0 (14–41) 35.0 (27–36)
Treatment duration (months)
Mean (SD) 30.6 (27.3) 37.4 (28.5) 10.3 (4.4)
Median (range) 19.5 (6–96) 30.0 (6–70) 10.5 (6–14)
Age at last follow-up (years)
Mean (SD) 28.6 (8.1) 26.3 (8.0) 35.5 (2.7)
Median (range) 25.0 (17–42) 24.5 (17–42) 36.0 (35–38)
Total clinical observation period (years)a
Mean (SD) 8.7 (7.8) 7.3 (7.2) 13.4 (9.3)
Median (range) 6.1 (1–25) 5.1 (1–25) 15.1 (3–22)
a Based on number of patients with available CFD data (n = 13 overall, n = 10 continued treatment patients, and n = 4 discontinued treatment
patients)
Fig. 1 CFD score progression over time. Data based on total
observation period across all patients. Zero time point on x-axis
represents start of miglustat treatment; thick coloured lines represent
average prediction based on linear mixed-effects analysis, and thinner
grey lines represent individual patient data
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Table 3 Absolute Cho/NAA ratio values in the centrum semi ovale over time of patients with NP-C
Time point Whole cohort (N = 16) Continued treatment
subgroup (N = 12)
Discontinued treatment
subgroup (N = 4)
Month 0 (baseline), na 14 11 3
Mean (SD) 0.63 (0.12) 0.64 (0.12) 0.57 (0.15)
Median (range) 0.62 (0.46–0.95) 0.64 (0.47–0.95) 0.51 (0.46–0.73)
Month 12, na 9 8 1
Mean (SD) 0.55 (0.08) 0.56 (0.08) 0.50 (NA)
Median (range) 0.55 (0.40–0.68) 0.55 (0.40–0.68) 0.50 (NA)
Month 18, na 8 5 3
Mean (SD) 0.56 (0.09) 0.54 (0.07) 0.60 (0.13)
Median (range) 0.56 (0.44–0.75) 0.57 (0.44–0.60) 0.56 (0.49–0.75)
Month 24, na 5 5 0
Mean (SD) 0.57 (0.26) 0.57 (0.26) NA
Median (range) 0.52 (0.36–1.02) 0.52 (0.36–1.02) NA
Month 36, na 4 3 1
Mean (SD) 0.56 (0.09) 0.54 (0.11) 0.61 (NA)
Median (range) 0.57 (0.44–0.65) 0.52 (0.44–0.65) 0.61 (NA)
Month 50, na 4 3 1
Mean (SD) 0.49 (0.12) 0.43 (0.07) 0.65 (NA)
Median (range) 0.47 (0.36–0.65) 0.45 (0.36–0.50) 0.65 (NA)
Month 72, na 1 1 0
Mean (SD) 0.53 (NA) 0.53 (NA) NA
Median (range) 0.53 (NA) 0.53 (NA) NA
All measurements were within 2 months of the stated time point
a n = number of patients with measurements per time point
Fig. 2 Progression of Cho/NAA ratios over time. Zero time point
represents the start of follow-up period; thick coloured lines represent
average prediction based on linear mixed modelling analysis, and
thinner grey lines represent individual patient profiles. Dashed
horizontal line represents normal values based on values from
healthy controls (Personal Communication, D Galanaud, 2014)
Fig. 3 Annual progression rates for CFD score versus Cho/NAA
ratio. Data from linear mixed-effects analysis. The thick central line is
linear regression best-fit line. Circles are data from continued patients
and crosses are data from discontinued patients
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Discussion
In a previous, preliminary study we observed long-term
longitudinal changes and normalisation of choline/creatine
ratios in three NP-C patients during miglustat therapy, as
measured using H-MRS. This indicated the possibility that
such H-MRS parameters may be useful as non-invasive
surrogate markers of disease progression and treatment
efficacy in this disease [8]. In this follow-up, observational
study we have extended our initial findings, this time based
on the Cho/NAA ratio, in a larger series of 16 adult
miglustat-treated NP-C patients over a period of up to
8.7 years. Similar to our previous observation of decreased
choline/creatine ratios over 24 months in miglustat-treated
patients, the current data indicate sustained reductions in
Cho/NAA ratio during long-term, continued miglustat
therapy. Baseline mean (SD) Cho/NAA ratios were higher
than control values observed during a separate exploratory
study in 12 healthy volunteers in our laboratory (Galanaud
D, personal communication, 2014), but average values
decreased to control levels by month 24 of treatment. This
occurred in parallel with stabilisation of clinical disease
manifestations (as indicated by CFD scores), which again
is in line with previous data [23]. In addition, and perhaps
most importantly, changes in the Cho/NAA ratio appeared
to correlate with the rate of clinical disease progression.
A major problem in previous trials assessing miglustat
in NP-C has been the lack of suitable objective markers
that could serve as efficacy endpoints. Neurological
examination can be objectified using a number of neuro-
logical scales. However, such scales are not fully appro-
priate for trials in diseases where only small cohorts of
patients can be observed, and where the goal is to stabilise
neurological manifestations rather than improve neurolog-
ical lesions that have already occurred. A study conducted
by Bowman et al. [3] provided preliminary evidence that
brain volumetric measurements may be of use as a more
objective and quantitative measure of disease progression
in NP-C, but further studies are required to fully evaluate
the utility of this approach.
Besides allowing observation of longitudinal changes in
Cho/NAA ratio, our findings suggest that H-MRS data may
also assist clinical decisions on an individual patient basis.
For instance, only three patients (14, 7 and 16) had normal
Cho/NAA values before treatment, among whom two (14
and 16) had to stop treatment after 6 and 7 months,
respectively, due to adverse effects that overcame any
clinical benefit. It is noteworthy that these patients had
relatively low rates of disease progression before treatment,
which suggests that together with seemingly normal brain
function, they did not have very active disease at the time
of treatment initiation. We may hypothesise that treatment
with miglustat is more beneficial in patients with high
baseline Cho/NAA values (indicating more active disease),
but is less so in slowly progressing patients. Miglustat
therapy might therefore best be introduced cautiously in
patients with normal Cho/NAA ratio. Conversely, patients
13 and 15, who both discontinued treatment after
14 months due to perceived lack of efficacy, had very high
Cho/NAA ratios ([0.61) after 6–12 months of treatment,
which suggests that lack of improvement in Cho/NAA
values might be predictive of low treatment response (e.g.,
based on CFD progression).
Overall, these findings need to be confirmed in a larger
patient cohort, as some patients in the current study who
showed good clinical response to treatment (e.g., patient 4)
also had a high Cho/NAA value even after 12 months.
Nevertheless, a working hypothesis could be that the higher
the Cho/NAA ratio, the better the expected treatment effect
with miglustat, but that above a certain threshold, a highly
active disease process might preclude beneficial drug
effects.
It is interesting to note that miglustat treatment had to be
continued for a prolonged period (approximately
24 months) in order to achieve normalisation and stabili-
sation of the mean Cho/NAA ratio. This long-term effect is
consistent with the mechanism of action of miglustat,
which slows down ganglioside synthesis but does not
increase the turnover of already accumulated lipids. The
half-life of lipids in cell membranes can be very long; that
of cholesterol has been estimated to range in the years in
humans [2]. Thus, our data, albeit based on a small cohort,
suggest that the effect of miglustat on brain lipids is quite
slow.
This study has several limitations. Firstly, we lacked a
well-matched control untreated patient group for compar-
ison. The data indicate that clinical neurological impair-
ment (based on CFD score) increases with time, and that
this impairment decreased during miglustat treatment in
parallel with improvements in the Cho/NAA ratio. How-
ever, we were only able to compare this treatment effect
with estimated pre-treatment data, which was limited to
only a few observations in the four patients in the early
discontinuation group.
Overall, this study shows reductions in nervous system
dysfunction in adults with NP-C during miglustat therapy.
We suggest that H-MRS could be used both as a marker for
the follow-up as well as a predictor of treatment
effectiveness.
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